Amgen halts Vectibix combo trial
Executive Summary
In an interim analysis of the study PACCE, Amgen finds that patients receiving Vectibix (panitumumab) combined with Genentech's Avastin (bevacizumab) and standard chemotherapy for treatment of first-line metastatic colorectal cancer had less chance of survival than patients receiving Avastin and chemotherapy alone. The EGFR inhibitor received accelerated approval on the basis of demonstrated improvement in progression-free survival in September, but failed to show an effect on overall survival. Amgen is continuing Phase III trials of Vectibix as a single agent in combination with chemotherapy...